345 Treatment with amlitelimab—a novel non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody—reduces IL-22 serum levels in a phase 2a randomized, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis

Autor: Stephan Weidinger, Michael Cork, Adam Reich, Thomas Bieber, Sally Gilbert, Nuala Brennan, Rosamund Wilson, Davide Lucchesi, Natalie Rynkiewicz, Marisa Stebegg, Ben Porter-Brown

Publikováno v: British Journal of Dermatology. 188

OX40Ligand (OX40L) upregulation on antigen-presenting cells (APCs) following antigen presentation contributes to the survival and functional activation of T helper (Th) 2 and Th1/17/22 cells, which are central to the inflammation and pathological out

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c993193a1c30df3c8c411ada4daf8a89
https://doi.org/10.1093/bjd/ljac140.039

OX40L Inhibition suppresses KLH-driven immune responses in healthy volunteers

Autor: Mahdi Saghari, Pim Gal, Sally Gilbert, Martin Yateman, Ben Porter‐Brown, Nuala Brennan, Sonia Quaratino, Rosamund Wilson, Hendrika W. Grievink, Erica S. Klaassen, Kirsten R. Bergmann, Jacobus Burggraaf, Martijn B. A. Doorn, John Powell, Matthijs Moerland, Robert Rissmann

Publikováno v: Clinical Pharmacology & Therapeutics, 111(5), 1121-1132. WILEY
Clinical Pharmacology and Therapeutics, 111(5), 1121-1132. Wiley-Blackwell
Clinical Pharmacology & Therapeutics, 111(5), 1121-1132

The safety, tolerability, immunogenicity, and pharmacokinetic (PK) profile of an anti-OX40L monoclonal antibody (KY1005, currently amlitelimab) were evaluated. Pharmacodynamic (PD) effects were explored using keyhole limpet hemocyanin (KLH) and tetan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b192edac11ba0b76d50af7f90aca16d
https://hdl.handle.net/1887/3483886